The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol

Journal of Psychiatric Research

Volumn 18, Issue 3, 1984, Pages 255-268

  Silverstone, Trevor ^a   Cookson, John ^a   Ball, Rosemary ^a   Chin, Cheuk Ngen ^a   Jacobs, David ^a   Lader, Susan ^a,b   Gould, Susan ^a,c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^c Janssen Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PIMOZIDE; PROLACTIN I 125; RADIOISOTOPE; SPIPERONE H 3; UNCLASSIFIED DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DOPAMINE RECEPTOR BLOCKING; DRUG MECHANISM; DRUG THERAPY; HUMAN; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RADIOIMMUNOASSAY; SCHIZOPHRENIA; THERAPY;

ACUTE DISEASE; ADULT; AGED; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIMOZIDE; PROLACTIN; RADIOIMMUNOASSAY; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 0021193643     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-3956(84)90016-5     Document Type: Article

References (31)

1. Receptor activity and turnover of dopamine and noradrenaline after neuropletics
2. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol and seru m prolactin
3. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations
4. Dose dopamine play a role in schizophrenia?
5. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
6. Pimozide in the treatment of newly-admitted schizophrenic patients
7. Clinical use of the radioreceptor assay for neuroleptics
8. The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intraveous test does of haloperidol
9. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuropleptic medication
10. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
11. A single and sensitive radioreceptor assay for antischizophrenic drugs in blood
12. The timecourse of the anti-psychotic effect in schizophrenia
13. Pimozide in acute schizophrenia: a pilot study
14. Pimozide versus haloperidol in acute schizophrenia: a double-blind controlled study
15. Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study
16. A radioreceptor assay for neuroleptic drugs in plasma
17. Human prolactin responses to neuroleptic drugs correlate with anti-schizophrenic potency
18. Plasma pimozide profiles in chronic schizophrenia
19. Relationship of serum haloperidol levels to clinical response in schizophrenic patients
20. Radioimmunoassay of the neuroleptic drug pimozide
21. Development of a schizophrenia scale sensitive to change
22. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients
23. Haloperidol plasma/red blood cell ratios and clinical efficacy
24. Comparison of pimozide and chlorpromazine in schizophrenia
25. High dose pimozide in the treatment of acutely agitated schizophrenia
26. Clinical state plasma levels of haloperidol and prolactin a correlation study in chronic schizophrenia
27. The prolactin secretory response to neurleptic drugs: mechanism, applications and limitations
28. High dose pimozide in acutely ill, newly admitted schizophrenic in-patients
29. Research diagnostic criteria: rationale and reliability
30. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients
31. Clinical significance of plasma chlorpromazine levels–I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment